玻璃体内注射康柏西普对渗出性老年性黄斑变性患者脉络膜厚度的影响

发布时间：2018-03-24 20:58

  本文选题：老年性黄斑变性　切入点：脉络膜厚度　出处：《眼科新进展》2016年12期

【摘要】：目的观察玻璃体内注射康柏西普对渗出性老年性黄斑变性(age-related macular degeneration,AMD)患者脉络膜厚度(choroidal thickness,CT)的影响。方法确诊为渗出性AMD患者42例42眼,分为典型AMD(typical-AMD,t AMD)组和息肉样血管病变(polypoidal choroidal vasculopathy,PCV)组,均行3+PRN方案的玻璃体内注射康柏西普治疗。采用光学相干断层扫描的增强深度成像技术测量治疗前及初次治疗后1个月、2个月、3个月、6个月治疗眼及对侧眼中心凹下脉络膜厚度(subfoveal choroidal thickness,SFCT)及距离中心凹1 mm的鼻侧和颞侧CT,对比分析康柏西普治疗前后的CT变化。结果渗出性AMD患眼玻璃体内注射康柏西普后1个月、2个月、3个月、6个月SFCT分别为(223.55±30.71)μm、(221.52±33.37)μm、(214.43±31.81)μm、(214.93±31.41)μm;治疗后6个月鼻侧CT从(225.40±43.97)μm减少至(205.71±42.20)μm,颞侧CT从(235.21±47.22)μm降至(203.52±39.15)μm;与基线相比,差异均具有统计学意义(均为P0.001)。其中,t AMD组SFCT从(234.06±41.04)μm减至(209.19±32.14)μm,PCV组从(274.60±27.73)μm减至(233.30±21.08)μm,各随访时间点所测SFCT与基线时相比差异均具有统计学意义(均为P0.05),而对侧正常眼6个月各时间点SFCT无明显改变。结论玻璃体内注射康柏西普会引起渗出型AMD(t AMD和PCV)CT降低。
[Abstract]:Objective to observe the effect of intravitreous injection of Compactopril on choroidal thickness#en0# in patients with exudative age-related macular degeneration (AMDD). Methods 42 patients (42 eyes) with exudative AMD were divided into two groups: typical type choroidal choroidal vasculopathy group and polypoidal choroidal vasculopathy group. All patients were treated with 3 PRN intravitreal injection of Compathopril. Enhanced depth imaging with optical coherence tomography was used to measure the eyes and contralateral eyes before treatment and 1 month, 2 months, 3 months and 6 months after initial treatment. The CT changes of subfoveal choroidal thicknessnessus and nasal and temporal CTs 1 mm away from the fovea were compared and analyzed before and after the treatment. Results 1 month, 2 months and 3 patients with exudative AMD were treated by intravitreous injection of Compactopril. In 6 months, SFCT were 223.55 卤30.71 渭 m, 221.52 卤33.37) 渭 m, 214.43 卤31.81 渭 m, 225.40 卤43.97 渭 m, 225.40 卤43.97 渭 m, 205.71 卤42.20 渭 m respectively, and temporal CT decreased from 235.21 卤47.22) 渭 m to 203.52 卤39.15 渭 m, compared with baseline, after 6 months of treatment, the nasal CT decreased from 225.40 卤43.97 渭 m to 205.71 卤42.20 渭 m, and the temporal CT decreased from 235.21 卤47.22 渭 m to 203.52 卤39.15 渭 m. The difference was statistically significant (P 0.001), in which the SFCT of t AMD group was reduced from 234.06 卤41.04 渭 m to 209.19 卤32.14 渭 m from 274.60 卤27.73 渭 m to 233.30 卤21.08 渭 m. The SFCT measured at all follow-up time points was significantly higher than that at baseline (all P0.05a, while the contralateral normal eyes were 6 months). Conclusion Intravitreous injection of Combortopril can induce the decrease of exudative AMD(t AMD and PCV)CT.
【作者单位】： 浙江医院眼科;
【分类号】：R774.5
，

本文编号：1660002